Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy

Leukemia
M EngelhardtM A Moore

Abstract

Telomerase activity and telomere length in mononuclear cells (MNCs) and granulocytes from peripheral blood (PB) and bone marrow (BM) specimens were studied in pediatric acute leukemia (ALL, n = 15; AML, n = 11) and pediatric solid tumor (ST) patients (n = 9) at diagnosis, during and after chemotherapy. In four ST patients, tumor tissue was also available. For comparative analysis, MNCs from healthy donors (n = 53) were analyzed. Telomerase was evaluated using a modified telomeric repeat amplification protocol (TRAP) assay, and telomere length by terminal restriction fragment (TRF) analysis. At diagnosis, high telomerase activity was detected in MNCs from all leukemia patients, which was similar to the activity from ST biopsy specimens. This exceeded by 10- to 20-fold the activity in PB MNCs from ST patients and healthy donors (P < 0.05). Granulocyte fractions lacked telomerase activity in all groups. BM MNCs in leukemia patients revealed a four-fold higher telomerase activity than PB (P = 0.005). After induction chemotherapy and response to treatment, telomerase activity decreased to borderline or undetectable levels in PB MNCs in leukemia (P < 0.01). Average telomeres in PB MNCs from pediatric patients were significantly longe...Continue Reading

Citations

Nov 18, 2000·Mechanisms of Ageing and Development·U FriedrichU Klotz
Feb 8, 2008·Nature Reviews. Cancer·Calvin B Harley
Dec 19, 1998·British Journal of Haematology·R F WynnN G Testa
Nov 11, 1999·British Journal of Haematology·F LeteurtreE Gluckman
Dec 17, 2009·The New England Journal of Medicine·Rodrigo T Calado, Neal S Young
Aug 22, 2007·Rejuvenation Research·Gesche TallenKarl Riabowol
May 29, 2004·Journal of Pediatric Hematology/oncology·Sophia Polychronopoulou, Paraskevi Koutroumba
Dec 13, 2012·Genome Biology·Matthew ParkerUNKNOWN Pediatric Cancer Genome Project
May 15, 2010·Future Oncology·Michelle F MaritzKaren L MacKenzie
Jan 11, 2014·Mutation Research. Fundamental and Molecular Mechanisms of Mutagenesis·Natalia S PavioloAlejandro D Bolzán
Dec 18, 2012·Leukemia & Lymphoma·Talia Diker-CohenMeir Lahav
May 29, 2007·Cancer Investigation·Uri Tabori, Jeffrey S Dome
Nov 14, 1998·Annals of Medicine·V UrquidiS Goodison
Oct 30, 2008·Ultrastructural Pathology·Sebastien LepreuxMarie-Laure Martin-Negrier
Jun 26, 2012·The International Journal of Biochemistry & Cell Biology·Ping LiDawei Xu
Dec 28, 2007·Mechanisms of Ageing and Development·Sharon A Savage, Blanche P Alter
Dec 15, 2015·Mutation Research. Genetic Toxicology and Environmental Mutagenesis·Natalia S PavioloAlejandro D Bolzán
Dec 12, 2003·European Journal of Haematology·Alejandra CottliarIrma Slavutsky
Sep 6, 2012·Journal of Cellular and Molecular Medicine·Rafael Díaz de la GuardiaPaola E Leone
Aug 4, 2004·Leukemia Research·Monika EngelhardtYalin Guo
Aug 23, 2005·Leukemia Research·Emel GürkanFikri Başlamişli
Feb 19, 2002·Oncogene·Lea Harrington, Murray O Robinson
Dec 22, 2014·Breast Cancer Research and Treatment·C Benitez-BuelgaJ Benitez
Feb 14, 2006·European Journal of Medical Genetics·Sukru PalanduzJørn Koch
May 10, 2002·Leukemia & Lymphoma·Tadeusz Robak, Agata Wrzesień-Kuś

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.